OCRA has invested $122 million into the research that leads to better understandings of all types of ovarian cancer, and better outcomes for everyone impacted by the disease. In fact, this year we are making our largest investment in research initiatives to date. OCRA researchers are working tirelessly toward learning more about the origins of the disease, the biological mechanisms that affect tumor growth, and immunological responses. Some of this involves known genetic mutations (such as BRCA 1 and 2, and lesser common mutations often found associated with rare ovarian cancer types such as STK11 and DICER1), and some of this research may discover new mutations that could be the cause of other subtypes of the disease. Furthermore, these investigators are looking beyond the ovaries, gaining new understandings of how other parts of the female reproductive tract impact tumor growth in the ovaries. Just as we now know that the most common and lethal form of ovarian cancer begins in the fallopian tubes, researchers believe that some subtypes of ovarian cancer arise in the endometrium. And of course, we are funding researchers who are working to improve treatment options. But while all of this is happening, while we are investing in the research that will improve outcomes for everyone facing an ovarian cancer diagnosis, we would be derelict in our duties if we did not also do everything we can to prevent people from getting this disease in the first place.